country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P11908

Copy Link Print Information

PQK7

PQK7 is an α-synuclein (α-synuclein) binder with a K_d value of 4 μM. PQK7 binds to key residues in the NAC region of ⍺-Syn, enhances the fluctuation of ⍺-Syn, reduces β-sheet content, maintains the solubility of ⍺-Syn monomers, and preserves the normal function of the protein. PQK7 reduces the toxicity of ⍺-Syn aggregates, restores cell cycle progression, decreases apoptosis (apoptosis), and inhibits ROS production. PQK7 can be used for the research of Parkinson's disease.

For research use only. We do not sell to patients.

Formula: C₃₂H₅₆N₁₀O₁₁
Molecular Weight:756.85

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Custom Peptide Synthesis

PQK7 Chemical Structure

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All α-synuclein Isoforms :

In Vitro

ApoptosisAβ/Tau/α-Synuclein AggregationCell Cycle RegulationOxidative Stress

Apoptosis

PQK7 (2 μM; 36 h fibril formation, 24 h cell treatment) significantly reduces late apoptosis and necrosis induced by α-Syn fibril treatment for 24 h in SH-SY5Y cells, while slightly increasing the level of early apoptosis^[1].

Aβ/Tau/α-Synuclein Aggregation

PQK7 (2.5-70 μM; 7-32 h) inhibits α-Syn fibril formation, reduces ThT fluorescence by approximately 40% after 30 h, and exhibits sustained inhibitory activity over time, but does not disrupt pre-formed fibrils^[1].
PQK7 (2-20 μM; 24 h) reduces β-sheet formation of α-Syn monomers and induces the transition of this protein to a random coil conformation^[1].
PQK7 (2.5 μM; 0-48 h) reduces the number and size of α-Syn aggregates^[1].
PQK7 (2.5 μM; 12-32 h) maintains α-Syn in a soluble state during the fibrosis process^[1].
PQK7 (2.5-70 μM; ~48 h) reduces the seeding activity of α-Syn fibrillation products; additionally, at concentrations of 2.5-30 μM for 30 h, it inhibits preformed fibril-induced secondary α-Syn fibrillation^[1].
PQK7 (2 μM; 24 h) reduces the nucleation of α-Syn monomers on preformed α-Syn fibrils^[1].

Cell Cycle Regulation

PQK7 (2 μM; 24 h) reduces α-Syn aggregate-induced cytotoxicity in SH-SY5Y cells and restores cell viability after 24 h of treatment^[1].
PQK7 (2 μM; 36 h fibril formation, 24 h cell treatment) restores normal cell cycle progression in SH-SY5Y cells treated with 36 h-aged α-Syn fibrils, reverses the decrease in the proportion of G1-phase cells, and reduces the proportion of cells entering the apoptotic sub-G1 phase after 24 h of treatment^[1].

Oxidative Stress

PQK7 (2-70 μM; 6 h) reduces intracellular ROS levels induced by α-Syn aggregates in SH-SY5Y cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

SH-SY5Y neuroblastoma cells
Concentration:

2 μM (used during α-Syn aggregate formation); 70 μM (PQK7 alone)
Incubation Time:

24 h
Result:

Mitigated α-Syn aggregate-induced cytotoxicity when used at 2 μM during aggregate formation.
Maintained ~97% cell viability at 70 μM when used alone, near untreated control levels.

Apoptosis Analysis^[1]

Cell Line:

SH-SY5Y cells
Concentration:

2 μM (used during α-Syn aged fibril formation)
Incubation Time:

36 h (fibril formation); 24 h (cell treatment)
Result:

Reduced late apoptosis from 18.8% to 4.84% and necrosis from 7.26% to 0.91% compared to α-Syn aged fibrils alone.
Slightly increased early apoptosis to 7.96% compared to controls.

Cell Cycle Analysis^[1]

Cell Line:

SH-SY5Y cells
Concentration:

2 μM (used during α-Syn aged fibril formation)
Incubation Time:

36 h (fibril formation); 24 h (cell treatment)
Result:

Restored G1 phase cells from 43.62% to 65.76% compared to α-Syn aged fibrils alone.
Reduced sub-G1 (apoptotic) cells from 36.35% to 8.78%, similar to untreated control cells.

Related Protocols :

Chemical Information

Molecular Weight 756.85
Formula C₃₂H₅₆N₁₀O₁₁
Sequence

Pro-Gln-Lys-Thr-Val-Glu-Gly-NH2
Sequence Shortening

PQKTVEG-NH2
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Motamedi M, et al. PQK7: A novel peptide inhibitor targeting alpha-synuclein fibrillogenesis in Parkinson's disease. Neuropeptides. 2025 Jun;111:102522. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote